Risk factors associated with high linezolid trough plasma concentrations

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 9, 2016, Pages 1183-1187

  Morata, L ^a   De la Calle, C ^a   Gomez Cerquera J M ^a   Manzanedo, L ^a   Casals, G ^a   Brunet, M ^a   Cobos Trigueros, N ^a   Martinez J A ^a   Mensa, J ^a   Soriano, A ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Glomerular filtration; linezolid; therapeutic drug monitoring; toxicity

Indexed keywords

AMIODARONE; AMLODIPINE; CREATININE; CYCLOSPORIN A; HEMOGLOBIN; LINEZOLID; RIFAMPICIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BLOOD SAMPLING; BONE AND JOINT INFECTIONS; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONTINUOUS RENAL REPLACEMENT THERAPY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; GRAM POSITIVE INFECTION; HEMODIALYSIS; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LEUKOCYTE COUNT; LIMIT OF QUANTITATION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMUM PLASMA CONCENTRATION; OBSERVATIONAL STUDY; PNEUMONIA; RETROSPECTIVE STUDY; SKIN INFECTION; SOFT TISSUE INFECTION; THROMBOCYTE COUNT; AGED; BACTERIAL INFECTIONS; BLOOD; CHEMICALLY INDUCED; DOSE RESPONSE; KIDNEY DISEASE; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; LINEZOLID; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84966706401     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2016.1182154     Document Type: Article

References (38)

1. D.M.Livermore Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemoth. 2003;51(Suppl 2):ii916.
2. R.G.Wunderink, M.S.Niederman, M.H.Kollef, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012;54:621–629.
3. C.A.DeRyke, T.P.LodiseJr, M.J.Rybak, et al. Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest. 2005;128:1414–1422.
4. H.Jiang, R.N.Tang, J.Wang. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials. Eur J Clin Microbiol. 2013;32:1121–1128.
5. M.J.Rybak, R.L.Akins. Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options. Drugs. 2001;61:1–7.
6. D.J.Stalker, G.L.Jungbluth, N.K.Hopkins, et al. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemoth. 2003;51:1239–1246.
7. J.G.Slatter, D.J.Stalker, K.L.Feenstra, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C] linezolid to healthy human subjects. Drug Metab Dispos. 2001;29:1136–1145.
8. G.E.Stein, E.M.Wells. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Curr Med Res Opin. 2010;26:571–588.
9. D.E.Wiskirchen, A.Shepard, J.L.Kuti, et al. Determination of tissue penetration and pharmacokinetics of linezolid in patients with diabetic foot infections using in vivo microdialysis. Antimicrob Agents Chemoth. 2011;55:4170–4175.
10. Y.Tsuji, Y.Hiraki, K.Matsumoto, et al. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother. 2011;17:70–75.• This article is considerably important as it was one of the first studies that associated a higher frequency of toxicity with higher linezolid concentrations.
11. D.Cattaneo, G.Orlando, V.Cozzi, et al. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int J Antimicrob Ag. 2013;41:586–589.
12. Y.Hiraki, Y.Tsuji, M.Hiraike, et al. Correlation between serum linezolid concentration and the development of thrombocytopenia. Scand J Infect Dis. 2012;44:60–64.
13. F.Pea, P.Viale, P.Cojutti, et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemoth. 2012;67:2034–2042.•• This article is considerably important as it demonstrated the reduction of toxicity while retaining efficacy by means of therapeutic drug monitoring.
14. E.Rubinstein, R.Isturiz, H.C.Standiford, et al. Worldwide assessment of linezolid’s clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemoth. 2003;47:1824–1831.
15. K.Attassi, E.Hershberger, R.Alam, et al. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis. 2002;34:695–698.
16. K.Matsumoto, A.Takeshita, K.Ikawa, et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Ag. 2010;36:179–181.•• This article is considerably important as it was one of the first studies that associated a higher frequency of toxicity with higher linezolid concentrations.
17. A.Soriano, J.Gómez, L.Gómez, et al. Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur J Clin Microbiol. 2007;26:353–356.
18. M.Zoller, B.Maier, C.Hornuss, et al. Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. Crit Care. 2014;18:R148.
19. C.Adembri, S.Fallani, M.I.Cassetta, et al. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Ag. 2008;31:122–129.
20. L.Morata, M.Cuesta, J.F.Rojas, et al. Risk factors for a low linezolid trough plasma concentration in acute infections. Antimicrob Agents Chemoth. 2013;57:1913–1917.
21. T.Yagi, T.Naito, M.Doi, et al. Plasma exposure of free linezolid and its ratio to minimum inhibitory concentration varies in critically ill patients. Int J Antimicrob Ag. 2013;42:329–334.
22. L.Foj Capell, A.Soriano Viladomiu, M.Brunet Serra, et al. Determinación de linezolid en plasma mediante cromatografía líquida de alta resolución para la monitorización terapéutica en pacientes. Rev Lab Clin. 2011;4:207–213.
23. K.Matsumoto, A.Shigemi, A.Takeshita, et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Ag. 2014;44:242–247.• This is an interesting study as it developed a nomogram suggesting different initial daily doses depending on the creatinine clearance.
24. Y.Nukui, S.Hatakeyama, K.Okamoto, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemoth. 2013;68:2128–2133.
25. L.M.Boak, C.R.Rayner, M.L.Grayson, et al. Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemoth. 2014;58:2334–2343.
26. Y.Tsuji, E.Yukawa, Y.Hiraki, et al. Population pharmacokinetic analysis of linezolid in low body weight patients with renal dysfunction. J Clin Pharmacol. 2013;53:967–973.
27. C.Roger, L.Muller, S.C.Wallis, et al. Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. J Antimicrob Chemoth. 2016;71:464–470.
28. H.Y.Dong, J.Xie, L.H.Chen, et al. Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients. Eur J Clin Microbiol. 2014;33:1029–1035.
29. S.Abe, K.Chiba, B.Cirincione, et al. Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. J Clin Pharmacol. 2009;49:1071–1078.
30. T.Niwa, A.Suzuki, S.Sakakibara, et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin Ther. 2009;31:2126–2133.
31. T.Sasaki, H.Takane, K.Ogawa, et al. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemoth. 2011;55:1867–1873.
32. F.Pea, M.Furlanut, P.Cojutti, et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemoth. 2010;54:4605–4610.
33. K.Gandelman, T.Zhu, O.A.Fahmi, et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol. 2011;51:229–236.• This is an important article as it was one of the first studies that evaluated the interaction between rifampin and linezolid.
34. I.Hoyo, J.Martínez-Pastor, S.Garcia-Ramiro, et al. Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections. Scand J Infect Dis. 2012;44:548–550.
35. C.Pauli-Magnus, S.Rekersbrink, U.Klotz, et al. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. N-S Arch Pharmakol. 2001;364:551–557.
36. I.S.Haslam, K.Jones, T.Coleman, et al. Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84) epithelial cells. Brit J Pharmacol. 2008;154:246–255.
37. H.Egle, R.Trittler, K.Kümmerer, et al. Linezolid and rifampin: drug interaction contrary to expectations? Clin Pharmacol Ther. 2005;77:451–453.
38. F.Pea, P.Cojutti, L.Dose, et al. A one-year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds? Br J Clin Pharmacol. 2015. doi:10.1111/bcp.12806.